Hytn Innovations Expands Pharma License, Adds Peptide Separation

Expanded License Opens API Production Path

Health Canada's amended license allows Hytn to produce pharmaceutical-grade cannabinoid APIs under Good Manufacturing Practice (GMP) standards, a regulatory threshold required for clinical trials and prescription drug development. The Vancouver-based company previously held a standard cannabis processing license limited to consumer products. The upgrade positions Hytn to supply raw cannabinoid materials to pharmaceutical manufacturers developing prescription formulations.

Hytn's extraction facility in British Columbia now operates under dual licensing: recreational cannabis processing and pharmaceutical API production. The company didn't disclose capital investment required for GMP compliance upgrades.

Peptide Separation Technology Enters Pharma Pipeline

Hytn announced partnerships with two unnamed pharmaceutical companies to apply its proprietary peptide separation technology to non-cannabis therapeutic compounds. The technology, originally developed to isolate minor cannabinoids from full-spectrum extracts, uses chromatography to separate peptide chains by molecular weight. It's a big shift.

The peptide separation platform extends beyond cannabis into mainstream pharmaceutical applications, targeting chronic pain and metabolic disease treatments where peptide purity determines efficacy.

Hytn expects to generate licensing revenue from the pharmaceutical partners by Q3 2026, according to a company statement. No financial terms were disclosed. The partnerships mark Hytn's first non-cannabis commercial agreements, opening a new chapter for the firm's revenue model.

Strategic Shift Toward Pharma Margins

The pharmaceutical pivot reflects broader industry migration away from low-margin recreational markets toward regulated medical channels. Canadian licensed producers face sustained price compression in adult-use cannabis — wholesale flower prices have declined 68% since 2020 according to Statistics Canada data.

Hytn's pharmaceutical strategy targets three revenue streams:

• Cannabinoid API sales to prescription drug developers
• Peptide separation licensing fees from pharmaceutical partners
• Contract manufacturing for clinical-stage cannabinoid therapies

The company operates a 40,000-square-foot extraction facility in Kelowna, British Columbia. Hytn didn't disclose current production capacity or revenue projections for the pharmaceutical division.

For background on pharmaceutical cannabis partnerships in North America, see the CannIntel topic hub on Cannabis Pharmaceutical Partnerships.